Precigen, Inc. (PGEN) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 2.71B USD. 52-week range 2.99 to 8.98 USD. Data as of 2026-10-09.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell ...